Breast Cancer Clinical Trial
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Summary
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Eligibility Criteria
Inclusion Criteria:
Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned
A biopsy clip placed at the time of diagnostic biopsy
18 years of age or older
Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint - this is justified as there is no individual benefit to study participation
Able to provide written consent prior to any research related activities
Exclusion Criteria:
Stage IV breast cancer
T4 breast cancer
Previous ipsilateral breast cancer
Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast biopsy between chemotherapy and surgery
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Minneapolis Minnesota, 55455, United States
How clear is this clinincal trial information?